Keyphrases
Gemcitabine
100%
Colorectal Cancer
74%
Overall Survival
72%
Chemotherapy
65%
Phase I Study
64%
Stage III Colon Cancer
61%
Disease-free Survival
53%
Phase II Study
47%
Tumor
43%
Pancreatic Adenocarcinoma
35%
Short-course Radiation Therapy
34%
Oxaliplatin
34%
Maximum Tolerated Dose
34%
Confidence Interval
33%
Stable Disease
32%
Hepatocellular Carcinoma
32%
Pancreatic Cancer
32%
Phase II Trial
32%
Advanced Biliary Tract Cancer
32%
Bevacizumab
31%
Metastatic Colorectal Cancer (mCRC)
31%
5-fluorouracil (5-FU)
31%
Advanced Hepatocellular Carcinoma
29%
Pegylated Liposomal Doxorubicin
29%
Solid Tumors
29%
Dose Escalation
29%
Complete Response
27%
Physical Activity
25%
Clinical Complete Response
24%
Partial Response
24%
Resection
24%
Recommended Phase 2 Dose
23%
Temsirolimus
23%
Rectal Adenocarcinoma
23%
Dose-limiting Toxicity
23%
Progression-free Survival
23%
Chemoradiation
22%
Placebo
22%
Biliary Tract Cancer
21%
Radiation Therapy
21%
Capecitabine
20%
Phase I Trial
20%
Median Overall Survival
20%
Phase 1 Study
20%
Nonoperative Management
19%
Median Progression-free Survival
19%
In Cancer
19%
Biphenotypic
19%
Metastatic Pancreatic Ductal Adenocarcinoma
19%
FOLFOX Chemotherapy
18%
Pharmacology, Toxicology and Pharmaceutical Science
Gemcitabine
89%
Neoplasm
80%
Diseases
77%
Chemotherapy
76%
Overall Survival
76%
Pancreas Adenocarcinoma
55%
Malignant Neoplasm
53%
Solid Malignant Neoplasm
49%
Colon Carcinoma
49%
Progression Free Survival
48%
Chemoradiation Therapy
45%
Liver Cell Carcinoma
43%
Disease Free Survival
41%
Adverse Event
37%
Doxorubicin
37%
Colorectal Carcinoma
36%
Fluorouracil
36%
Biliary Tract Cancer
36%
Oxaliplatin
33%
Rectum Cancer
32%
Pancreas Cancer
29%
Maximum Tolerated Dose
27%
Bevacizumab
26%
Metastatic Colorectal Cancer
25%
Irinotecan
25%
Paclitaxel
24%
Clinical Trial
24%
Temsirolimus
23%
Recurrent Disease
22%
Pharmacokinetics
20%
Placebo
19%
Capecitabine
19%
Diarrhea
18%
Docetaxel
17%
Folinic Acid
17%
Cisplatin
15%
HIV
14%
Phase II Trials
14%
Neutropenia
14%
Phase I Trials
14%
Monoclonal Antibody
14%
Adenocarcinoma
14%
Epidermal Growth Factor Receptor
13%
Leukemia
13%
Neuroendocrine Tumor
13%
Randomized Clinical Trial
13%
Chimeric Protein
12%
Sorafenib
11%
Binimetinib
11%
Interferon
11%
Medicine and Dentistry
Neoplasm
74%
Gemcitabine
72%
Radiation Therapy
71%
Overall Survival
67%
Rectum Cancer
51%
Diseases
48%
Malignant Neoplasm
44%
Hepatocellular Carcinoma
37%
Biliary Tract Cancer
36%
Colorectal Carcinoma
35%
Surgery
34%
Progression Free Survival
34%
Cholangiocarcinoma
32%
Disease Free Survival
32%
Pancreas Adenocarcinoma
30%
Colon Carcinoma
29%
Cancer
29%
Pancreas Cancer
29%
Chemoradiotherapy
28%
Arm
24%
FOLFOX
23%
Fluorouracil
22%
Oxaliplatin
20%
Bevacizumab
20%
Metastatic Colorectal Cancer
18%
Epidermal Growth Factor Receptor
18%
Rectum Carcinoma
17%
Clinical Trial
16%
Magnetic Resonance Imaging
15%
Monoclonal Antibody
15%
Recurrent Disease
15%
Cisplatin
15%
Surgical Margin
14%
Capecitabine
14%
Circulating Tumor DNA
14%
Placebo
14%
Metastatic Carcinoma
13%
Fluorine-18
13%
Hazard Ratio
13%
Gastrointestinal Stromal Tumor
13%
Interferon
13%
Solid Malignant Neoplasm
12%
Lymph Node
12%
Survival Time
12%
Adjuvant Chemotherapy
12%
Poly ADP Ribose Polymerase
11%
Cell-Free DNA
11%
Preoperative Treatment
11%
Human Study
11%
Microsphere
11%